Title: Expanding the mutational spectrum of the ABCB4 gene in inherited adult cholestatic liver disorders with four novel pathogenic variants: case reports

Authors: Minh Tuan Huynh, Jean-Louis Delaunay, Laure Muller, Christophe Corpechot, Cong Toai Tran, Véronique Barbu

DOI: 10.17235/reed.2018.5828/2018
Link: PubMed (Epub ahead of print)


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Expanding the mutational spectrum of the \( ABCB4 \) gene in inherited adult cholestatic liver disorders with four novel pathogenic variants: case reports

Minh-Tuan Huynh\textsuperscript{1,3}, Jean-Louis Delaunay\textsuperscript{2}, Laure Muller\textsuperscript{1}, Christophe Corpechot\textsuperscript{4}, Cong Toai Tran\textsuperscript{1} and Véronique Barbu\textsuperscript{1,2}

\textsuperscript{1}Laboratoire Commun de Biologie et Génétique Moléculaires. Hôpitaux Universitaires Est Parisien. Hôpital Saint-Antoine. Paris, France. \textsuperscript{2}Sorbonne Université. INSERM. CRSA. Paris, France. \textsuperscript{3}Pham Ngoc Thach Medical University. Ho Chi Minh City, Viet Nam. \textsuperscript{4}Centre de Référence des Maladies Inflammatoires des Voies Biliaires et Hépatites Auto-immunes. Service d’Hépatologie. Hôpital Saint-Antoine. Paris, France

Received: 11/04/2018
Accepted: 22/09/2018

Correspondence: Minh-Tuan Huynh. Laboratoire Commun de Biologie et Génétique Moléculaires. Hôpitaux Universitaires Est Parisien. Hôpital Saint-Antoine. 184 Rue du Faubourg Saint-Antoine. 75012 Paris, France
e-mail: minhtuannia82@yahoo.it

Ethics statement: This work is not clinical research and is considered as routine clinical care.

ABSTRACT

Low phospholipid-associated cholelithiasis and intrahepatic cholestasis of pregnancy are two MDR3-related inherited liver disorders caused by biallelic or monoallelic \( ABCB4 \) loss-of-function variants. Low phospholipid-associated cholelithiasis is clinically characterized by the early onset of symptomatic cholelithiasis in young adults while intrahepatic cholestasis of pregnancy is a distinct clinical entity associated with adverse fetal outcomes. Of note, patients carrying \( ABCB4 \) sequence variations commonly exhibit phenotypic expression over a wide continuum due to
environmental and hormonal contributing factors and genetic modifiers. Patients with an early diagnosis of MDR3-related diseases could benefit from ursodeoxycholic acid treatment in order to prevent acute and chronic complications as well as adverse pregnancy outcomes. We herein report five patients with an overlapping phenotype from low phospholipid-associated cholelithiasis to intrahepatic cholestasis of pregnancy, harboring five ABCB4 missense variants, four of which were novel. Our study highlights the phenotypic and genetic heterogeneity of inherited cholestatic liver diseases and also expands the mutation spectrum of ABCB4 sequence variations in adult cholestatic liver diseases.

**Key words:** Low phospholipid-associated cholelithiasis syndrome. Intrahepatic cholestasis of pregnancy. Novel ABCB4 loss-of-function variants. Targeted next-generation sequencing.

**INTRODUCTION**

ABCB4 (MIM *171060) encodes a phospholipid floppase that translocates phosphatidylcholine from the inner to the outer leaflet of the apical (canalicular) membrane of the hepatocyte. Low phospholipid-associated cholelithiasis syndrome (LPAC syndrome) (MIM #600803) is a recent entity of liver disorders characterized by a) the onset of biliary symptoms before the age of 40, b) microlithiasis or intrahepatic sludge on imaging and c) the recurrence of symptoms after cholecystectomy. The syndrome is caused by biallelic or monoallelic ABCB4 “loss-of-function” variants. Severe biliary complications including acute pancreatitis, recurrent cholangitis, segmental spindle-shape dilatation of the biliary tree filled with gallstones, secondary sclerosing cholangitis and adverse fetal complications in intrahepatic cholestasis of pregnancy (ICP), which are commonly observed in patients with LPAC syndrome (1,2). ICP is characterized by jaundice and pruritus associated with abnormal values of hepatobiliary-injury biomarkers, including raised serum bile acid concentrations. Adverse pregnancy outcomes include spontaneous preterm labor, fetal distress, fetal asphyxia events and third trimester intrauterine death. Furthermore, the genetic heterogeneity of ICP could hamper the etiological diagnosis and clinical management. ICP (MIM #614972) is caused by heterozygous sequence variations of at least five different genes including ABCB4, ABCB11, ATP8B1, NRIH4 and TJP2 (3). We report
herein five patients with an overlapping phenotype, from LPAC syndrome to ICP. Targeted next-generation sequencing identified five \textit{ABCB4} missense variants, four of which were novel. After having reviewed the literature, a molecular analysis and genotype-phenotype correlation were established.

**CASE REPORT**

\textit{P1} is a 27-year-old female patient who experienced ICP. Her mother was diagnosed with ICP at the age of 20 and symptomatic biliary gallstones at the age of 30. The proband began to experience episodes of biliary colic at the age of 18 and underwent endoscopic biliary sphincterotomy. Moreover, she presented pruritus associated with a disturbance of the liver function while taking oral contraceptives, which quickly resolved after drug discontinuation at the age of 25. She exhibited intense pruritus with elevated transaminases (AST 108 UI/l, ALT 164 UI/l, GGT 253 UI/l, total bilirubin 28 µmol/l, ALP 385 UI/l and bile acids 85 µmol/l) at 20 weeks of gestational age and received continued ursodeoxycholic acid treatment until delivery. Itching was persistent and less severe after delivery, predominantly on the trunk and lower limbs at night.

\textit{P2} is a 21-year-old female who was diagnosed with ICP at 24 weeks of gestational age. She presented with intense pruritus at night, mainly on her trunk and lower limbs. Her liver function tests showed elevated levels of AST of 75 UI/l, ALT at 110 UI/l, GGT at 95 UI/l, PAL at 155 UI/l and bile acids of at 50 µmol/l. Her mother (\textit{P3}) had a history of LPAC syndrome and ICP, she also had a family history of gallstone disease; her mother, two sisters and two uncles underwent a cholecystectomy. The proband was referred to our clinic due to intrahepatic microlithiasis and dilatation of the bile ducts in the left liver; a gallstone of 14 mm in the common bile duct was also identified via endoscopic ultrasound. She exhibited anicteric cholestasis, recurrent right upper quadrant abdominal pain over the last two years, which was relieved by paracetamol treatment. She had no pruritus and angiocholitis. Her initial liver function tests showed increased serum levels of ALAT (110 UI/l), GGT (225 UI/l) and ALP (320 UI/l) but a normal bilirubin level. She underwent biliary sphincterotomy for the removal of biliary gallstones and cholecystectomy and also had a positive response to ursodeoxycholic acid.
treatment.

*P4* is a 34-year-old female who was hospitalized in the Gastroenterology Service due to diarrhea and abdominal pain. She had a history of cholestasis, nephroblastoma with hepatic metastasis and ICP. She underwent a nephrectomy at the age of 16, a partial hepatectomy (segment IV) due to nephroblastoma metastasis at the age of 17 and a cholecystectomy at the age of 27. The index-patient had multiple episodes of epigastric pain after meals, vomiting and nausea. Abdominal ultrasound identified multiple intrahepatic microlithiasis. Her biological liver function tests showed levels of GGT at 157 UI/l, PAL at 140 UI/l and total bilirubin at 19 µmol/l. On clinical physical examination, her abdomen was soft and the epigastric and right hypochondrium regions were sensitive with palpation. She was diagnosed with LPAC syndrome and underwent ursodeoxycholic acid treatment with dose of 10 mg/kg per day.

*P5* is a 23-year-old female with symptomatic gallstone disease. She underwent a cholecystectomy at the age of 24 and had recurrent epigastric pain radiating to the right hypochondrium, which increased after meals. Her liver function tests showed an increased level of ASAT at 150 UI/l, ALAT of 110 UI/l, GGT of 320 UI/l and ALP of 245 UI/l but normal total bilirubin levels. Abdominal ultrasound identified an image of comet-tails and moderate dilatation of intrahepatic bile ducts, particularly the common bile duct. She was treated with ursodeoxycholic acid at 2 x 250 mg per day.

**RESULTS**

Targeted next-generation sequencing identified five *ABCB4* missense variants (NM_000443), four of which were novel. Of interest, one patient (P3) with LPAC syndrome and ICP carried compound heterozygous *ABCB4* missense variants c.2540T>C p.Ile847Thr and c.140G>A p.Arg47Gln (Fig. 1), while her daughter (P2) was heterozygous for the c.2540T>C p.Ile847Thr variant. Three patients (P1, P4 and P5) with LPAC syndrome and ICP carried three novel *ABCB4* missense variants, c.1280T>C p.Leu427Pro, c.1766A>C p.His589Pro and c.832A>G p.Arg278Gly, respectively (Table 1 and Fig. 2). Moreover, heterozygous *ABCG8* c.55G>C p.Asp19His (rs11887534) and homozygous *ABCB11* c.1331T>C p.Val444Ala functional polymorphisms were also detected in P1 (4-6).
DISCUSSION

LPAC syndrome and ICP are two common hereditary liver diseases in young adults caused by *ABCB4* “loss-of-function” variants. However, the phenotypic and genetic heterogeneity of liver diseases and the wide phenotypic expression often hamper the clinical diagnosis. We report five patients with LPAC syndrome and ICP carrying *ABCB4* sequence variations. Most patients had a family history of gallstone disease among first-degree relatives. We identified three novel missense variants, c.1280T>C p.Leu427Pro, c.1766A>C p.His589Pro and c.832A>G p.Arg278Gly, in three unrelated patients with ICP and LPAC syndrome (P1, P4, P5). These variants were all predicted to be detrimental (SIFT, Polyphen-2, Mutation Taster). Two missense variants, c.1280T>C p.Leu427Pro and c.1766A>C p.His589Pro, are located in the NBD1 domain (Nucleotide Binding Domain 1), which is highly conserved and important for MDR3 protein function. In addition, one family with cholestatic liver disorders including LPAC syndrome and ICP was observed. The mother (P3) had LPAC syndrome and ICP and she was compound heterozygous for *ABCB4* missense variants, c.2540T>C p.Ile847Thr and c.140G>A p.Arg47Gln. The rare variant, c.2540T>C p.Ile847Thr (rs769944852) has a MAF of 8.248x10^-6 (1/121240) according to the ExAc databases and was predicted to be deleterious by Polyphen-2 and Mutation Taster. Of interest, another patient with severe LPAC syndrome and *ABCB4* compound heterozygous variants c.140G>A p.Arg47Gln and c.1217G>A p.Arg406Gln was previously recorded (7). It is widely agreed that *ABCB4* missense variants could cause a milder or variable phenotype spectrum due to the residual protein activity. Consequently, some patients with LPAC syndrome carry compound heterozygous *ABCB4* missense variants and one could argue that the synergetic effects of two missense variants would lead to a reduced MDR3 protein activity below a critical threshold to cause the clinical phenotype (8). Moreover, the presence of additional genetic modifiers, such as heterozygous *ABCG8* c.55G>C p.Asp19His and homozygous *ABCB11* c.1331T>C p.Val444Ala, also contribute to the variable clinical phenotype and the disease severity. In conclusion, our study reports five patients with cholestatic liver disease carrying four novel *ABCB4* sequence variants and expands the mutational spectrum of *ABCB4* sequence variations in LPAC syndrome and ICP. Of note, our report highlights the wide
phenotypic variations of inherited liver disorders (9) as well as the contribution of targeted next-generation sequencing for the diagnostic work-up in patients with cholestatic liver diseases. *ABCB4*-mutated patients could benefit from early ursodeoxycholic treatment to prevent acute, chronic and adverse fetal complications.

REFERENCES

Table 1. Novel and potential *ABCB4* disease-associated sequence variations identified in patients with cholestatic liver disease

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>cDNA</th>
<th>Protein nomenclature</th>
<th>In silico prediction</th>
<th>Mutation Taster</th>
<th>Functional polymorphism</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>c.1280T&gt;C</td>
<td>p.Leu427Pro</td>
<td>Deleterious</td>
<td>Probably damaging</td>
<td>Disease causing</td>
</tr>
<tr>
<td>P2</td>
<td>c.2540T&gt;C</td>
<td>p.Ile847Thr</td>
<td>Tolerated</td>
<td>Probably damaging</td>
<td>Disease causing</td>
</tr>
<tr>
<td>P3</td>
<td>c.2540T&gt;C</td>
<td>p.Ile847Thr</td>
<td>Tolerated</td>
<td>Probably damaging</td>
<td>Disease causing</td>
</tr>
<tr>
<td></td>
<td>c.140G&gt;A</td>
<td>p.Arg47Gln</td>
<td>Deleterious</td>
<td>Probably damaging</td>
<td>Disease causing</td>
</tr>
<tr>
<td>P4</td>
<td>c.1766A&gt;C</td>
<td>p.His589Pro</td>
<td>Deleterious</td>
<td>Probably damaging</td>
<td>Disease causing</td>
</tr>
<tr>
<td>P5</td>
<td>c.832A&gt;G</td>
<td>p.Arg278Gly</td>
<td>Deleterious</td>
<td>Probably damaging</td>
<td>Disease causing</td>
</tr>
</tbody>
</table>
Fig. 1. A. Familial pedigree: mother (P3) was compound heterozygous for $ABCB4$ missense variants and her daughter (P2) was heterozygous for an $ABCB4$ missense variant. B. Sanger sequencing showing compound heterozygous $ABCB4$ missense variants, c.2540T>C p.Ile847Thr and c.140G>A p.Arg47Gln in the mother.